This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Amgen, Inc.

Drug Names(s): veliflaplon, DG-031

Description: DG031 is a small-molecule inhibitor of the 5-lipoxygenase activating protein, or FLAP, encoded by a gene that may be linked to significantlyincreased risk of heart attack. FLAP regulates the first step in the biochemical pathway that leads to the synthesis of leukotriene B4 (LTB4), a potent promoter of inflammation.

Deal Structure: On November 17, 2003, deCODE announced that it had acquired an exclusive worldwide license from Bayer AG to develop and commercialize DG031. Bayer will receive milestones as the compound advances towards market approval, as well as royalties on sales of the compound as a marketed drug.

Saga and deCODE
In January 2010, deCODE announced that it completed the sale of its Iceland-based subsidiary deCODE genetics ehf (also known as Islensk erfdagreining) and its drug discovery and development programs to Saga Investments LLC.

Amgen and deCODE
In December 2012, Amgen and deCODE Genetics announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics. The acquisition closed in January 2013.

Partners: Bayer AG

DG031 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug